- Home
- ABEO vs JRI Comparison
ABEO vs JRI Comparison
Compare ABEO & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABEO | JRI |
|---|---|---|
| Founded | 1974 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.5M | 357.4M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABEO | JRI |
|---|---|---|
| Price | $5.34 | $12.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 128.9K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.38% |
| EPS Growth | ★ 165.16 | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,024.31 | N/A |
| Revenue Next Year | $145.42 | N/A |
| P/E Ratio | $5.34 | ★ N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $11.67 |
| 52 Week High | $7.54 | $14.37 |
Technical Indicators
Market Signals| Indicator | ABEO | JRI |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 53.17 |
| Support Level | $5.24 | $12.70 |
| Resistance Level | $5.62 | $13.38 |
| Average True Range (ATR) | 0.24 | 0.14 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 55.38 | 33.33 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest
Nuveen Real Asset Income and Growth Fund is a closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.